Core Viewpoint - The company has successfully developed an automated, intelligent, and integrated desktop synthesis system for antibody-drug conjugates (ADC) and nucleotide monomers in collaboration with East China Normal University, which enhances R&D efficiency and service quality [1] Group 1 - The full subsidiary of the company, Shanghai Ruizhi Pharmaceutical Research Group Co., Ltd., has partnered with East China Normal University to develop the new synthesis system [1] - The new system allows for seamless transition from laboratory research to industrial production, indicating a significant advancement in the production process [1] - The implementation of this system is expected to significantly shorten the R&D cycle and improve overall research efficiency [1]